https://attrubyhcp.com/

BridgeBio is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials and includes the recent approval of Attruby (acoramidis) in November 2024. 

Visit us online at BridgeBio.com or stop by our booth at the conference to learn more.

Contact Information:

Holly Barnish
[email protected]
(608) 320-3058